HOUSE AMENDMENT

Bill No. CS/CS/HB 7095 (2011)

| | Amendment No. |
|-----|--|
| | CHAMBER ACTION |
| | Senate House |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| 1 | Representative Schenck offered the following: |
| 2 | |
| 3 | Amendment |
| 4 | Remove lines 1651-1667 and insert: |
| 5 | chapter 458, chapter 459, chapter 459, chapter 461, or chapter |
| 6 | 466 and pharmacies that would purchase or otherwise receive from |
| 7 | the wholesale distributor controlled substances listed in |
| 8 | Schedule II or Schedule III as provided in s. 893.03. The |
| 9 | wholesale distributor shall maintain records of such |
| 10 | credentialing and make the records available to the department |
| 11 | upon request. Such credentialing must, at a minimum, include: |
| 12 | 1. A determination of the clinical nature of the receiving |
| 13 | entity, including any specialty practice area. |
| 14 | 2. A review of the receiving entity's history of Schedule |
| 15 | II and Schedule III controlled substance purchasing from the |
| 16 | wholesale distributor. |
| _ ~ | 260773 |
| | Approved For Filing: 4/19/2011 1:38:41 PM |
| | Page 1 of 2 |

HOUSE AMENDMENT

Bill No. CS/CS/HB 7095 (2011)

Amendment No.

17 3. A determination that the receiving entity's Schedule II

18 and Schedule III controlled substance purchasing history, if

19 any, is consistent with and reasonable for that entity's

20 <u>clinical business needs.</u>

21

4. Conduct of a level 2 background screening